"GLP-1 Diabetes Drug Shows Promise in Slowing Parkinson's Progression"

New data from a French academic trial published in the New England Journal of Medicine suggests the potential for treating Parkinson’s disease with a GLP-1 agonist, although the impact so far is modest and important questions remain. The study adds to the growing body of research indicating the potential of the GLP-1 drug class to treat a wide range of conditions beyond diabetes and obesity, including kidney and heart disease, sleep apnea, and depression.